# Phase 1a/b Study on Safety of IMX101 in H. Pylori-negative and H. Pylori-infected Healthy Volunteers

> **NCT03270800** · PHASE1 · COMPLETED · sponsor: **ImevaX** · enrollment: 72 (actual)

## Conditions studied

- Helicobacter Pylori Infected Subjects
- Helicobacter Pylori Naive Subjects

## Interventions

- **BIOLOGICAL:** CTA control
- **BIOLOGICAL:** IMX101 vaccine

## Key facts

- **NCT ID:** NCT03270800
- **Lead sponsor:** ImevaX
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-30
- **Primary completion:** 2018-12-23
- **Final completion:** 2018-12-23
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2019-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03270800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03270800, "Phase 1a/b Study on Safety of IMX101 in H. Pylori-negative and H. Pylori-infected Healthy Volunteers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03270800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*